Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
2359.HK
603259.SHG
Lepu Biopharma gets taste of spring with first revenues
The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…
2157.HK
Zai Lab sees profits on the horizon as commercialization accelerates
The innovative drug maker’s loss narrowed last year, as it forecast potential profitability as soon as 2025 on fast-growing revenues Key Takeaways: Zai Lab is set to reach several product…
9688.HK
ZLAB.US
CanSino looks for next growth shot in ‘life after Covid’
The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
6185.HK
688185.SHG
FAST NEWS: Clover Bio Gets Exclusive Rights for Imported Flu Vaccine
The latest: Clover Biopharmaceuticals Ltd. (2197.HK) said on Monday it has reached an exclusive agreement to import Adimmune Corp.’s quadrivalent seasonal influenza vaccine AdimFlu-S (QIS) to China. It added it will…
Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
FAST NEWS: CStone Raises $50 Million in New Share Placement
The latest: CStone Pharmaceuticals (2616.HK) on Wednesday announced it placed 84.8 million new shares at a price of HK$4.633 per share, raising approximately HK$393 million ($50.4 million). The sale price…
Recent Articles
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
2359.HK
603259.SHG
CanSino looks for next growth shot in ‘life after Covid’
6185.HK
688185.SHG
